Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Growth (Status and Outlook) 2021-2026

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Years Considered
• 1.3 Research Objectives
• 1.4 Market Research Methodology
• 1.5 Research Process and Data Source
• 1.6 Economic Indicators
• 1.7 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size 2016-2026
  • 2.1.2 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Region 2020 VS 2021 VS 2026
• 2.2 NTRK Fusion Gene Positive Advanced Solid Tumor Segment by Type
  • 2.2.1 Therapeutics
  • 2.2.2 Therapeutics
• 2.3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type
  • 2.3.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Type
  • 2.3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Type (2016-2021)
• 2.4 NTRK Fusion Gene Positive Advanced Solid Tumor Segment by Application
  • 2.4.1 Hospitals and Clinics
  • 2.4.2 Cancer Centers
  • 2.4.3 Others
• 2.5 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application
  • 2.5.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size CAGR by Application
  • 2.5.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Application (2016-2021)

3 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Players

• 3.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Market Share by Players
  • 3.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue by Players (2019-2021E)
  • 3.1.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Revenue Market Share by Players (2019-2021E)
• 3.2 Global NTRK Fusion Gene Positive Advanced Solid Tumor Key Players Head office and Products Offered
• 3.3 Market Concentration Rate Analysis
  • 3.3.1 Competition Landscape Analysis
  • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2019-2021E)
• 3.4 New Products and Potential Entrants
• 3.5 Mergers & Acquisitions, Expansion

4 NTRK Fusion Gene Positive Advanced Solid Tumor by Regions

• 4.1 NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Regions (2016-2021)
• 4.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2016-2021)
• 4.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2016-2021)
• 4.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2016-2021)
• 4.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size Growth (2016-2021)

5 Americas

• 5.1 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Country (2016-2021)
• 5.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2016-2021)
• 5.3 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2016-2021)
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Brazil

6 APAC

• 6.1 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Region (2016-2021)
• 6.2 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2016-2021)
• 6.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2016-2021)
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia

7 Europe

• 7.1 Europe NTRK Fusion Gene Positive Advanced Solid Tumor by Country (2016-2021)
• 7.2 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2016-2021)
• 7.3 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2016-2021)
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia

8 Middle East & Africa

• 8.1 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor by Region (2016-2021)
• 8.2 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Type (2016-2021)
• 8.3 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Size by Application (2016-2021)
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Global NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast

• 10.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Regions (2021-2026)
  • 10.1.1 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Regions (2021-2026)
  • 10.1.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  • 10.1.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  • 10.1.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
  • 10.1.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Forecast
• 10.2 Americas NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Countries (2021-2026)
  • 10.2.1 United States NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.2.2 Canada NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.2.3 Mexico NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.2.4 Brazil NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
• 10.3 APAC NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2021-2026)
  • 10.3.1 China NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.3.2 Japan NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.3.3 Korea NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.3.4 Southeast Asia NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.3.5 India NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.3.6 Australia NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
• 10.4 Europe NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Country (2021-2026)
  • 10.4.1 Germany NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.4.2 France NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.4.3 UK NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.4.4 Italy NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.4.5 Russia NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
• 10.5 Middle East & Africa NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Region (2021-2026)
  • 10.5.1 Egypt NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.5.2 South Africa NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.5.3 Israel NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.5.4 Turkey NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
  • 10.5.5 GCC Countries NTRK Fusion Gene Positive Advanced Solid Tumor Market Forecast
• 10.6 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Type (2021-2026)
• 10.7 Global NTRK Fusion Gene Positive Advanced Solid Tumor Forecast by Application (2021-2026)

11 Key Players Analysis

• 11.1 Bayer
  • 11.1.1 Bayer Company Information
  • 11.1.2 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  • 11.1.3 Bayer NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2019-2021)
  • 11.1.4 Bayer Main Business Overview
  • 11.1.5 Bayer Latest Developments
• 11.2 Teva Pharmaceuticals
  • 11.2.1 Teva Pharmaceuticals Company Information
  • 11.2.2 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  • 11.2.3 Teva Pharmaceuticals NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2019-2021)
  • 11.2.4 Teva Pharmaceuticals Main Business Overview
  • 11.2.5 Teva Pharmaceuticals Latest Developments
• 11.3 Empire Genomics
  • 11.3.1 Empire Genomics Company Information
  • 11.3.2 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  • 11.3.3 Empire Genomics NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2019-2021)
  • 11.3.4 Empire Genomics Main Business Overview
  • 11.3.5 Empire Genomics Latest Developments
• 11.4 SeraCare Life Sciences
  • 11.4.1 SeraCare Life Sciences Company Information
  • 11.4.2 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  • 11.4.3 SeraCare Life Sciences NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2019-2021)
  • 11.4.4 SeraCare Life Sciences Main Business Overview
  • 11.4.5 SeraCare Life Sciences Latest Developments
• 11.5 F. Hoffmann-La Roche
  • 11.5.1 F. Hoffmann-La Roche Company Information
  • 11.5.2 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  • 11.5.3 F. Hoffmann-La Roche NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2019-2021)
  • 11.5.4 F. Hoffmann-La Roche Main Business Overview
  • 11.5.5 F. Hoffmann-La Roche Latest Developments
• 11.6 NeoGenomics Laboratories
  • 11.6.1 NeoGenomics Laboratories Company Information
  • 11.6.2 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Product Offered
  • 11.6.3 NeoGenomics Laboratories NTRK Fusion Gene Positive Advanced Solid Tumor Revenue, Gross Margin and Market Share (2019-2021)
  • 11.6.4 NeoGenomics Laboratories Main Business Overview
  • 11.6.5 NeoGenomics Laboratories Latest Developments
• 11.7 Glaxosmithkline
  • 11.7.1 Glaxosmithkline Company Information